Tech Company Financing Transactions

BiPar Sciences Funding Round

On 2/27/2007, BiPar Sciences raised $35 million in Series B funding from Domain Associates, Asset Management Ventures and Canaan Partners.

Transaction Overview

Company Name
Announced On
2/27/2007
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Proceeds Purpose
BiPar is developing multiple compounds designed to inhibit PARP 1 (poly-ADP-ribose polymerase), an enzyme that is crucial to cell repair and upregulated in certain tumors. The round fully funds the Company's robust Phase 2 program for its lead drug candidate, BSI-201, and accelerates development of two additional drug candidates from BiPar's pipeline.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 550
Brisbane, CA 94005
USA
Email Address
Overview
BiPar Sciences Inc. is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
Profile
BiPar Sciences LinkedIn Company Profile
Social Media
BiPar Sciences Company Twitter Account
Company News
BiPar Sciences News
Facebook
BiPar Sciences on Facebook
YouTube
BiPar Sciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Hoyoung Huh
  Hoyoung Huh LinkedIn Profile  Hoyoung Huh Twitter Account  Hoyoung Huh News  Hoyoung Huh on Facebook
Chief Financial Officer
John Schembri
  John  Schembri LinkedIn Profile  John  Schembri Twitter Account  John  Schembri News  John  Schembri on Facebook
Vice President
Barry Sherman
  Barry   Sherman LinkedIn Profile  Barry   Sherman Twitter Account  Barry   Sherman News  Barry   Sherman on Facebook
Vice President
Charles Bradley
  Charles Bradley LinkedIn Profile  Charles Bradley Twitter Account  Charles Bradley News  Charles Bradley on Facebook
VP - Marketing
Sunil Patel
  Sunil Patel LinkedIn Profile  Sunil Patel Twitter Account  Sunil Patel News  Sunil Patel on Facebook
VP - Regulatory Affairs
Deborah Thomas
  Deborah Thomas LinkedIn Profile  Deborah Thomas Twitter Account  Deborah Thomas News  Deborah Thomas on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/27/2007: Terascala venture capital transaction
Next: 2/27/2007: Advanced Biohealing venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary